PL1926483T3 - Leczenie chorób autoimmunologicznych - Google Patents
Leczenie chorób autoimmunologicznychInfo
- Publication number
- PL1926483T3 PL1926483T3 PL06793341T PL06793341T PL1926483T3 PL 1926483 T3 PL1926483 T3 PL 1926483T3 PL 06793341 T PL06793341 T PL 06793341T PL 06793341 T PL06793341 T PL 06793341T PL 1926483 T3 PL1926483 T3 PL 1926483T3
- Authority
- PL
- Poland
- Prior art keywords
- autoimmune diseases
- treatment
- neuritis
- uveitis
- invention describes
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 206010029240 Neuritis Diseases 0.000 abstract 2
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 150000001414 amino alcohols Chemical class 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71599005P | 2005-09-09 | 2005-09-09 | |
| PCT/EP2006/066150 WO2007028821A2 (en) | 2005-09-09 | 2006-09-07 | Treatment of autoimmune diseases |
| EP06793341A EP1926483B1 (en) | 2005-09-09 | 2006-09-07 | Treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1926483T3 true PL1926483T3 (pl) | 2011-05-31 |
Family
ID=37056992
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06793341T PL1926483T3 (pl) | 2005-09-09 | 2006-09-07 | Leczenie chorób autoimmunologicznych |
| PL10174280T PL2295049T3 (pl) | 2005-09-09 | 2006-09-07 | Leczenie chorób autoimmunologicznych |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10174280T PL2295049T3 (pl) | 2005-09-09 | 2006-09-07 | Leczenie chorób autoimmunologicznych |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20080200438A1 (pl) |
| EP (2) | EP2295049B1 (pl) |
| JP (4) | JP5244598B2 (pl) |
| KR (3) | KR20140117704A (pl) |
| CN (1) | CN101257899B (pl) |
| AT (1) | ATE489948T1 (pl) |
| AU (2) | AU2006289100B2 (pl) |
| BR (1) | BRPI0615906A2 (pl) |
| CA (2) | CA2820510A1 (pl) |
| CY (1) | CY1111285T1 (pl) |
| DE (1) | DE602006018629D1 (pl) |
| DK (2) | DK2295049T3 (pl) |
| ES (2) | ES2357426T3 (pl) |
| IL (2) | IL189665A (pl) |
| JO (1) | JO2655B1 (pl) |
| MA (1) | MA29787B1 (pl) |
| MX (1) | MX2008003170A (pl) |
| NO (1) | NO20081727L (pl) |
| NZ (2) | NZ566137A (pl) |
| PL (2) | PL1926483T3 (pl) |
| PT (2) | PT2295049E (pl) |
| RU (2) | RU2424795C2 (pl) |
| SG (1) | SG165364A1 (pl) |
| SI (2) | SI1926483T1 (pl) |
| TN (1) | TNSN08103A1 (pl) |
| TW (2) | TWI372620B (pl) |
| WO (1) | WO2007028821A2 (pl) |
| ZA (1) | ZA200801694B (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7781617B2 (en) * | 2004-07-16 | 2010-08-24 | Kyorin Pharmaceutical Co., Ltd | Effective use method of medicaments and method of preventing expression of side effect |
| EP2511262B1 (en) | 2004-10-12 | 2017-02-01 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxy-phenylthio)-2-chlorophenyl[ethyl]-1,3-propanediol hydrochloride |
| PT1932522E (pt) * | 2005-10-07 | 2012-06-26 | Kyorin Seiyaku Kk | Agente terapêutico para doenças do fígado contendo, como princípio activo, um derivado de 2- amino-1,3-propanodiol |
| TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
| MY146775A (en) * | 2006-08-08 | 2012-09-28 | Kyorin Seiyaku Kk | Amino alcohol derivative and immunosuppressive agent having same as an active ingredient |
| SG174028A1 (en) * | 2006-08-08 | 2011-09-29 | Kyorin Seiyaku Kk | Aminophosphoric acid ester derivative and s1p receptor modulator containing the same as active ingredient |
| WO2008099781A1 (ja) * | 2007-02-13 | 2008-08-21 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体を有効成分とする脱髄性疾患の治療剤又は予防剤 |
| US8476305B2 (en) | 2008-02-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Therapeutic agent or prophylactic agent for inflammatory bowel disease comprising amino alcohol derivative as active ingredient |
| NZ589412A (en) * | 2008-05-20 | 2012-11-30 | Kyorin Seiyaku Kk | Use of a sphingosine-1-phosphate (S1P) agonist for maintance of induced remission of autoimmune or inflammatory diseases after inital treatment |
| KR20110049870A (ko) * | 2008-08-18 | 2011-05-12 | 노파르티스 아게 | 탈수초성 말초 신경병증의 치료를 위한 아미노 알콜 유도체 |
| CN102869353A (zh) * | 2010-05-06 | 2013-01-09 | 诺瓦提斯公司 | 自身免疫疾病的治疗 |
| CA2794607A1 (en) * | 2010-05-06 | 2011-11-10 | Novartis Ag | Dosage regimen of diaryl sulfide derivatives |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5141421A (en) * | 1991-12-17 | 1992-08-25 | Carrier Corporation | Nested coupling mechanism for scroll machines |
| DE4428835A1 (de) * | 1994-08-01 | 1996-02-08 | Schering Ag | Neue 3-substituierte 3H-2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
| KR20000075745A (ko) * | 1997-02-27 | 2000-12-26 | 가마후라 아키오 | 의약 조성물 |
| CA2461212C (en) * | 2001-09-27 | 2010-08-17 | Kyorin Pharmaceutical Co., Ltd. | Diaryl sulfide derivatives, salts thereof and immunosuppressive agents using the same |
| DE60235900D1 (de) | 2001-09-27 | 2010-05-20 | Kyorin Seiyaku Kk | Osuppressivum |
| WO2004026817A1 (ja) | 2002-09-19 | 2004-04-01 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体とその付加塩及び免疫抑制剤 |
| BR0314760A (pt) * | 2002-09-24 | 2005-07-26 | Novartis Ag | Compostos orgânicos |
| NZ538842A (en) * | 2002-09-28 | 2008-03-28 | Mcneil Ppc Inc | Immediate release dosage form comprising a solid core of density 0.9 g/ml surrounded by a shell that is readily soluble to gastrointestinal fluids |
| EP2172472B1 (en) * | 2003-02-18 | 2012-12-26 | Kyorin Pharmaceutical Co., Ltd. | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor |
| BRPI0409250B8 (pt) * | 2003-04-08 | 2022-01-18 | Mitsubishi Pharma Corp | Composições farmacêuticas sólidas compreendendo um agonista receptor de s1p e um álcool do açúcar |
| WO2005014525A2 (en) * | 2003-08-12 | 2005-02-17 | Mitsubishi Pharma Corporation | Bi-aryl compound having immunosuppressive activity |
| PL1660449T3 (pl) * | 2003-08-28 | 2010-05-31 | Novartis Ag | Pochodne aminopropanolu |
| US7781617B2 (en) * | 2004-07-16 | 2010-08-24 | Kyorin Pharmaceutical Co., Ltd | Effective use method of medicaments and method of preventing expression of side effect |
| CA2589265A1 (en) * | 2004-11-29 | 2006-06-01 | Novartis Ag | Dosage regimen of an s1p receptor agonist |
| GB0504544D0 (en) * | 2005-03-04 | 2005-04-13 | Novartis Ag | Organic compounds |
-
2006
- 2006-09-07 PL PL06793341T patent/PL1926483T3/pl unknown
- 2006-09-07 JP JP2008529636A patent/JP5244598B2/ja active Active
- 2006-09-07 CN CN2006800328984A patent/CN101257899B/zh not_active Expired - Fee Related
- 2006-09-07 AU AU2006289100A patent/AU2006289100B2/en not_active Ceased
- 2006-09-07 PT PT10174280T patent/PT2295049E/pt unknown
- 2006-09-07 AT AT06793341T patent/ATE489948T1/de active
- 2006-09-07 ES ES06793341T patent/ES2357426T3/es active Active
- 2006-09-07 WO PCT/EP2006/066150 patent/WO2007028821A2/en not_active Ceased
- 2006-09-07 NZ NZ566137A patent/NZ566137A/en not_active IP Right Cessation
- 2006-09-07 EP EP10174280.7A patent/EP2295049B1/en not_active Not-in-force
- 2006-09-07 SG SG201006580-3A patent/SG165364A1/en unknown
- 2006-09-07 JO JO2006298A patent/JO2655B1/en active
- 2006-09-07 RU RU2008113187/15A patent/RU2424795C2/ru not_active IP Right Cessation
- 2006-09-07 SI SI200630937T patent/SI1926483T1/sl unknown
- 2006-09-07 MX MX2008003170A patent/MX2008003170A/es active IP Right Grant
- 2006-09-07 SI SI200631889T patent/SI2295049T1/sl unknown
- 2006-09-07 ES ES10174280.7T patent/ES2529724T3/es active Active
- 2006-09-07 CA CA2820510A patent/CA2820510A1/en not_active Abandoned
- 2006-09-07 CA CA2620554A patent/CA2620554C/en not_active Expired - Fee Related
- 2006-09-07 EP EP06793341A patent/EP1926483B1/en active Active
- 2006-09-07 NZ NZ588372A patent/NZ588372A/en not_active IP Right Cessation
- 2006-09-07 DK DK10174280.7T patent/DK2295049T3/en active
- 2006-09-07 PL PL10174280T patent/PL2295049T3/pl unknown
- 2006-09-07 PT PT06793341T patent/PT1926483E/pt unknown
- 2006-09-07 DE DE602006018629T patent/DE602006018629D1/de active Active
- 2006-09-07 BR BRPI0615906-0A patent/BRPI0615906A2/pt not_active IP Right Cessation
- 2006-09-07 US US12/065,096 patent/US20080200438A1/en not_active Abandoned
- 2006-09-07 KR KR1020147026128A patent/KR20140117704A/ko not_active Ceased
- 2006-09-07 DK DK06793341.6T patent/DK1926483T3/da active
- 2006-09-07 KR KR1020147001496A patent/KR101476591B1/ko not_active Expired - Fee Related
- 2006-09-07 RU RU2011111117/15A patent/RU2493840C2/ru not_active IP Right Cessation
- 2006-09-08 TW TW099117063A patent/TWI372620B/zh not_active IP Right Cessation
- 2006-09-08 TW TW095133326A patent/TWI376223B/zh active
-
2008
- 2008-02-21 ZA ZA200801694A patent/ZA200801694B/xx unknown
- 2008-02-21 IL IL189665A patent/IL189665A/en not_active IP Right Cessation
- 2008-03-06 TN TNP2008000103A patent/TNSN08103A1/en unknown
- 2008-03-17 MA MA30758A patent/MA29787B1/fr unknown
- 2008-04-07 NO NO20081727A patent/NO20081727L/no not_active Application Discontinuation
- 2008-04-08 KR KR1020087008413A patent/KR101476451B1/ko not_active Expired - Fee Related
-
2010
- 2010-09-21 AU AU2010224355A patent/AU2010224355B2/en not_active Ceased
-
2011
- 2011-03-01 CY CY20111100242T patent/CY1111285T1/el unknown
-
2012
- 2012-10-17 JP JP2012230044A patent/JP6077265B2/ja not_active Expired - Fee Related
-
2014
- 2014-06-23 IL IL233328A patent/IL233328A0/en unknown
- 2014-09-29 JP JP2014199069A patent/JP2015025002A/ja not_active Withdrawn
-
2016
- 2016-09-30 JP JP2016193400A patent/JP2017019854A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL233328A0 (en) | Treatment of autoimmune diseases | |
| TW200509892A (en) | Novel aminobenzophenone compounds | |
| WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2006058868A8 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| TW200806325A (en) | Therapeutic uses of inhibitors of RTP801 | |
| WO2005051914A8 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
| MX2011012015A (es) | Tratamiento de deterioro cognitivo leve y enfermedad de alzheimer. | |
| PL1910338T3 (pl) | Związki heterotetracykliczne jako mimetyki TPO | |
| WO2006058867A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| UA90698C2 (en) | Triazole substituted aminobenzophenone compounds | |
| WO2009136997A3 (en) | Inhibitors of human cathepsin l, cathepsin b, and cathepsin s | |
| TW200635597A (en) | Substituted pteridines for the treatment of inflammatory diseases | |
| WO2006078576A3 (en) | Aminomethyl beta-secretase inhibitors for the treatment of alzheimer's disease | |
| MX2010000956A (es) | Derivados de isoftalamida que inhiben actividad de beta-secretasa. | |
| MX2008002166A (es) | Compuestos y composiciones como mimeticos de trombopoietina (tpo). | |
| BR0306855A (pt) | Método para o tratamento de distúrbios cognitivos | |
| WO2007058862A3 (en) | Imidazolidinone compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease | |
| TW200633711A (en) | Substituted pteridines for the treatment of inflammatory diseases | |
| TW200639155A (en) | Thiazolidinones, their production and use as pharmaceutical agents | |
| IL181713A0 (en) | Use of il-17f for the treatment and/or prevention of neurological diseases | |
| WO2007019080A3 (en) | Tricyclic beta-secretase inhibitors for the treatment of alzheimer's disease | |
| TW200603791A (en) | Compounds and compositions as cathepsin S inhibitors | |
| CY1116051T1 (el) | Θεραπεια αυτοανοσων ασθενειων | |
| BRPI0402756A (pt) | método para o tratamento de distúrbios cognitivos | |
| MX2007003281A (es) | N-etilhidroxietilamina util en el tratamiento de afecciones del sistema nervioso central. |